Arterial stiffness progression in metabolic dysfunction-associated fatty liver disease subtypes: A prospective cohort study

被引:1
|
作者
Liu, Lei [1 ]
Zhou, Yufu
Deng, Shuwen [1 ]
Yuan, Ting [1 ]
Yang, Saiqi [1 ]
Zhu, Xiaoling [1 ]
Wang, Changfa [2 ]
Wang, Yaqin [1 ]
机构
[1] Cent South Univ, Xiangya Hosp 3, Hlth Management Ctr, Dept Gastroenterol, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp 3, Gen Surg Dept, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China
关键词
Arterial stiffness; Brachial ankle pulse wave velocity (baPWV); Metabolic dysfunction-associated fatty liver (MAFLD); Diabetes; ASIA-PACIFIC REGION; CARDIOVASCULAR-DISEASE; RISK-FACTORS;
D O I
10.1016/j.numecd.2024.03.030
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: We aimed to investigate the correlation and to explore which MAFLD subtypes have the greatest influence on progression of arterial stiffness risk. Methods and results: Using data from a health examination-based cohort, a total of 12,129 participants who underwent two repeated health examinations that included brachial-ankle pulse wave velocity (baPWV) from 2012 to 2020 were enrolled. Participants were separated into non-MAFLD, overweight/obese (OW-MAFLD), lean/normal weight (lean-MAFLD) and diabetes (DM-MAFLD) groups. Among the participants with a median follow-up of 2.17 years, 4511 (37.2%) participants had MAFLD at baseline, among which 3954 (87.7%), 123 (2.7%), and 434 (9.6%) were OW-, lean- and DM-MAFLD, respectively. Analyses using linear regression models confirmed that compared with the non-MAFLD group, the elevated baPWV change rates (cm/s/ year) were 12.87 (8.81-16.94), 25.33 (7.84-42.83) and 38.49 (27.88-49.10) in OW, lean and DM -MAFLD, respectively, while the increased change proportions (%) were 1.53 (1.10-1.95), 3.56 (1.72-5.40) and 3.94 (2.82-5.05), respectively. Similar patterns were observed when these two baPWV parameters were transformed in the form of the greatest increase using Cox proportional hazards model analyses. Furthermore, the risk of arterial stiffness progression across MAFLD subtypes presented a significant, gradient, inverse relationship in the order of DM-, lean-, OW with metabolic abnormalities (MA)-, and OW without MA-MAFLD. Conclusion: MAFLD, especially DM-MAFLD and lean-MAFLD, was significantly associated with arterial stiffness progression, providing evidence that stratification screening and surveillance strategies for CVD risk have important clinical implications. (c) 2024 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1890 / 1900
页数:11
相关论文
共 50 条
  • [21] Metabolic dysfunction-associated fatty liver disease is associated with increased risk of extrahepatic malignancies: a nationwide cohort study
    Park, Min Kyung
    Moon, Hye-Sung
    Chung, Sungwon
    Won, Sungho
    Lee, Yun Bin
    Cho, Eun Ju
    Lee, Jeong-Hoon
    Yu, Su Jong
    Yoon, Jung-Hwan
    Kim, Yoon Jun
    JOURNAL OF HEPATOLOGY, 2023, 78 : S630 - S630
  • [22] Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study
    Jung, Chan-Young
    Koh, Hee Byung
    Park, Keun Hyung
    Joo, Young Su
    Kim, Hyung Woo
    Ahn, Sang Hoon
    Park, Jung Tak
    Kim, Seung Up
    DIABETES & METABOLISM, 2022, 48 (04)
  • [23] Metabolic Dysfunction-associated fatty liver disease and incident heart failure risk: the Kailuan cohort study
    Zhihao Wei
    Zhe Huang
    Zongshuang Song
    Wenliu Zhao
    Dandan Zhao
    Yizhen Tan
    Shuohua Chen
    Peng Yang
    Yun Li
    Shouling Wu
    Diabetology & Metabolic Syndrome, 15
  • [24] The Role of Metabolic Dysfunction-Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study
    Wei, Suosu
    Song, Jian
    Xie, Yujie
    Huang, Junzhang
    Yang, Jianrong
    JMIR PUBLIC HEALTH AND SURVEILLANCE, 2023, 9
  • [25] Metabolic Dysfunction-associated fatty liver disease and incident heart failure risk: the Kailuan cohort study
    Wei, Zhihao
    Huang, Zhe
    Song, Zongshuang
    Zhao, Wenliu
    Zhao, Dandan
    Tan, Yizhen
    Chen, Shuohua
    Yang, Peng
    Li, Yun
    Wu, Shouling
    DIABETOLOGY & METABOLIC SYNDROME, 2023, 15 (01):
  • [26] Metabolic Dysfunction-Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study
    Lee, Hokyou
    Lee, Hye Won
    Kim, Seung Up
    Kim, Hyeon Chang
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2022, 13 (01) : E00435
  • [27] Metabolic dysfunction-associated fatty liver disease in the elderly with diabetic foot ulcers: A longitudinal cohort study
    Zhang, Liya
    Lin, Yuanmei
    Huang, Xiuxian
    Zhai, Zhenwei
    Wei, Rongyan
    Mo, Jiacheng
    Li, Junjun
    Lu, Wensheng
    INTERNATIONAL WOUND JOURNAL, 2024, 21 (04)
  • [28] METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE INCREASES COLON CANCER RISK: A NATIONWIDE COHORT STUDY
    Lee, Hye Won
    Kim, Seung Up
    GUT, 2021, 70 : A10 - A11
  • [29] LIVER FIBROSIS IN ASIANS WITH METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE
    Kim, Byung Ik
    Sohn, Won
    Kwon, Heon-Ju
    Cho, Yong Kyun
    HEPATOLOGY, 2021, 74 : 1022A - 1022A
  • [30] Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease
    Sohn, Won
    Kwon, Heon-Ju
    Chang, Yoosoo
    Ryu, Seungho
    Cho, Yong Kyun
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (05) : E1135 - E1148